Vaping and Smoking Project in People With Schizophrenia

Last updated: April 17, 2025
Sponsor: State University of New York at Buffalo
Overall Status: Active - Recruiting

Phase

N/A

Condition

Tourette's Syndrome

Mood Disorders

Schizotypal Personality Disorder (Spd)

Treatment

Ad libitum smoking/vaping

Acute (24-hour) abstinence

Clinical Study ID

NCT06944847
STUDY00006122-Supplement
3R01DA054276-03S1
  • Ages 21-50
  • All Genders

Study Summary

The proposed research will characterize withdrawal among people with schizophrenia who vape daily compared to people with schizophrenia who smoke combustible cigarettes daily, filling critical gaps in the understanding of electronic nicotine delivery systems (ENDS) dependence and contributing to the development of vaping cessation interventions amongst people with schizophrenia, the leading preventable cause of death in the US.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 6+ months of daily/near-daily nicotine vaping or cigarette smoking

  • 200+ ng/mL cotinine on a commercially-available quick screen

  • stable antipsychotic medication dose (no changes in past 6 months).

Exclusion

Current Exclusion Criteria:

  • intention to quit daily/near-daily vaping/smoking in the next month

  • current (2+ days out of the past 7) use of pipe tobacco, hookah/shisha, smokelesstobacco, dissolvable tobacco, nicotine pouches. For vaping group only, current (2+days out of past 7) use of cigars, cigarillos, or filtered cigars that are filledwith tobacco or a mix of tobacco and marijuana

  • current use of any smoking cessation medication

  • current severe substance dependence other than tobacco/nicotine (including cannabis;NIDA Modified ASSIST of 27+)

  • current (past 2 weeks) suicidal ideation with intent and/or plan

  • pregnancy (intake urine screen)

  • florid psychosis or severe cognitive symptoms (score of ≥5 on PANSS items delusions (P1), hallucinatory behavior (P3), or unusual thought content (G9), conceptualdisorganization (P2), abstract thinking (N5), or poor attention (G11) or a score ≥6on grandiosity (P5) or suspiciousness (P6)

Study Design

Total Participants: 64
Treatment Group(s): 2
Primary Treatment: Ad libitum smoking/vaping
Phase:
Study Start date:
February 15, 2025
Estimated Completion Date:
April 01, 2027

Study Description

Although withdrawal is considered a key feature of nicotine/tobacco addiction that contributes to difficulty quitting smoking and likely electronic nicotine delivery systems (ENDS; e.g., electronic cigarettes), there is currently no research on ENDS withdrawal in people with schizophrenia. The proposed supplement will conduct a systematic and comprehensive characterization of withdrawal in a sample of people with SCZ who vape daily compared to those who smoke daily, filling gaps in our understanding of ENDS dependence/withdrawal for people with SCZ and contributing to the identification of intervention targets for ENDS use.

Connect with a study center

  • University at Buffalo

    Buffalo, New York 14260
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.